Project
CAIN457Q12301
Automatically Closed ยท 2020 until 2023
Bartz-Batliner Mira, Hutz Carina Liane, Peischl Riana, Rubbert-Roth Andrea, Sasselli Clelia
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2020
End Date
2023
Financing
Industry
Study Design
A pivotal, randomized, double- blind, placebo controlled trial evaluating at week 52 the efficacy and safety of secukinumbab versus placebo in subjects with active LN also receiving background SoC regimen. Long- term efficacy, saftey and tolerability will be collected up to 2 years.
Brief description/objective
A two-year, phase III randomized, double-blind, parallel- group, placebo- controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo in combination with SoC therapy in patients with active lupus nephritis